ArticleInfection and drug resistance2024
Clinical Efficacy of Azithromycin in the Treatment of Pediatric
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive value of CCL26 and CCR3 levels for prognosis assessment in children withTranslational pediatrics · 2025Article
- Clinical efficacy of azithromycin-budesonide combination therapy in pediatric Mycoplasma pneumoniae pneumonia.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the clinical efficacy of azithromycin in the treatment of pediatric Methods: A comparison was made between the two groups regarding clinical treatment effects, recovery status, levels of blood indicators [C-reactive protein (CRP), white blood cell count (WBC), platelet count (PLT), D-dimer (D-D)], and the occurrence of adverse reactions. The control group received conventional symptomatic treatment, while the case group received both conventional treatment and azithromycin. Results: ① Clinical treatment effects: The total effective rate of treatment in the control group was 84.21%, while it was significantly higher at 96.83% in the case group (P < 0.05). ② Recovery status: After treatment, the case group exhibited significantly shorter durations for fever clearance, cough disappearance, rale disappearance, resolution of chest radiographic shadows, and hospital stay compared to the control group (P < 0.05). ③ Blood indicator levels: After treatment, the levels of C-reactive protein (CRP), white blood cell count (WBC), platelet count (PLT), and D-dimer (D-D) were significantly lower in the case group than in the control group, indicating an improvement in the inflammatory response and blood clotting status. Conclusion: Addition of azithromycin to conventional symptomatic treatment significantly improves the efficacy of Mycoplasma pneumoniae pneumonia treatment in children, reduces inflammatory response, improves blood circulation, further promotes recovery without a substantial increase in related adverse reactions, suggesting its relatively high safety in clinical application and advocating for its clinical promotion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.